Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 5 December 2019, 08:11 HKT/SGT
Share:
    

Source: Eisai
Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium

TOKYO, Dec 5, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest information on its in-house discovered and developed eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN, "eribulin") will be presented during the 42nd San Antonio Breast Cancer Symposium (SABCS2019). The symposium will be held from December 10 through 14, 2019, in San Antonio, Texas in the United States.




A total of five poster presentations will be given at this year's SABCS including the study results evaluating absolute lymphocyte count at the baseline with eribulin as a predictor of overall survival from the post-hoc analysis of two Phase III clinical studies of eribulin in patients with advanced or metastatic breast cancer.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Dec 5, 2019 08:11 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 9, 2019 08:36 HKT/SGT
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer's Disease Using Blood
Dec 9, 2019 08:17 HKT/SGT
Eisai Satisfies All-Case Surveillance Condition for Approval of Anti-Cancer Agent Lenvima in Treatment of Thyroid Cancer
Dec 2, 2019 08:23 HKT/SGT
Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer's Disease Conference
Dec 2, 2019 08:08 HKT/SGT
Eisai: Additional Indication for Lenvima (Lenvatinib) for Differentiated Thyroid Cancer Accepted in China
Nov 26, 2019 08:37 HKT/SGT
Eisai to Present Latest Data on Perampanel at the 73rd American Epilepsy Society Annual Meeting
Nov 20, 2019 13:01 HKT/SGT
Eisai's Equfina 50mg Tablets (Safinamide Mesilate) Launched in Japan
Nov 5, 2019 09:02 HKT/SGT
Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
Oct 23, 2019 10:13 HKT/SGT
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Oct 15, 2019 20:24 HKT/SGT
Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China
Oct 1, 2019 10:46 HKT/SGT
Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: